Information regarding activities. On or before January 20 of each year during the Term, ▇▇▇▇▇▇▇ shall provide Genmab’s Alliance Manager with a written report summarising, in reasonable detail, its activities conducted during the preceding Calendar Year with respect to the Development and Commercialisation of each Licensed Product. In addition, ▇▇▇▇▇▇▇ shall provide Genmab’s Alliance Manager within [***] calendar days of the end of each Calendar Quarter during the Term a written update setting out in reasonable detail any such activities not previously reported by ▇▇▇▇▇▇▇ to Genmab pursuant to this Clause and which details have not otherwise been provided to Genmab in writing. It is understood that the minutes of the JSC or Development Committee meetings may serve as written notice under this provision, to the extent that they fully report ▇▇▇▇▇▇▇’▇ Development and Commercialisation activities during the relevant
Appears in 2 contracts
Sources: License Agreement (Genmab a/S), License Agreement (Genmab a/S)